Teneligliptin 20 mg (Generic)

Product Overview

Teneligliptin 20 mg is a generic pharmaceutical product that contains the active ingredient Teneligliptin, classified as a dipeptidyl peptidase‑4 (DPP‑4) inhibitor. It is manufactured by Glenmark Pharmaceuticals Ltd., a globally recognized generic‑drug company with a strong track record of quality and regulatory compliance. The medication is supplied in strip packaging that holds 15 tablets per strip, and bulk pack sizes are available in 30, 60, and 90 tablets to accommodate varying treatment durations. This product is officially indicated for the management of type 2 diabetes mellitus and has received regulatory approval from agencies such as the U.S. Food and Drug Administration (FDA). For optimal stability, store the tablets at room temperature, away from moisture, heat, and direct sunlight, and keep the strip tightly closed until use.

What is Teneligliptin 20 mg

Teneligliptin belongs to the newer generation of DPP‑4 inhibitors designed to improve glycemic control in adults with type 2 diabetes. The 20 mg strength represents the standard therapeutic dose for once‑daily oral administration. As a generic medication, it contains the same active moiety as the reference‑listed drug but is offered at a cost‑effective price, increasing access for patients. Unlike insulin or sulfonylureas, Teneligliptin does not directly stimulate insulin secretion; instead, it enhances the body’s own incretin hormones, which are released in response to food intake.

Pharmacologically, Teneligliptin exhibits high selectivity for the DPP‑4 enzyme and possesses a half‑life that supports sustained activity over 24 hours, enabling convenient once‑daily dosing. Its pharmacokinetic profile is characterized by minimal metabolism via cytochrome P450 enzymes, which reduces the likelihood of drug‑drug interactions. The drug is primarily excreted unchanged through the kidneys, so dose adjustments are required in patients with impaired renal function. Detailed pharmacokinetic data can be reviewed through the NIH database.

Uses and Benefits

The primary clinical use of Teneligliptin 20 mg is to lower blood glucose levels in conjunction with diet and exercise in adults diagnosed with type 2 diabetes mellitus. Clinical trials have demonstrated that treatment leads to modest but clinically meaningful reductions in glycated hemoglobin (HbA1c) of approximately 0.5 to 0.8 percentage points compared with placebo. In addition to glycemic control, Teneligliptin is associated with weight neutrality, meaning patients typically do not experience significant weight gain or loss—a desirable attribute when compared with some sulfonylureas that can cause weight gain.

Another important benefit is the low propensity for hypoglycemia when used as monotherapy, because the drug’s mechanism of action is glucose‑dependent. This reduces the risk of dangerous low‑blood‑sugar episodes, especially in elderly patients. Some studies also suggest potential cardiovascular benefits, including modest improvements in blood pressure and lipid profiles, although further research is ongoing to fully elucidate these effects. The once‑daily dosing simplifies regimen adherence, and the availability of multiple pack sizes (30, 60, or 90 tablets) provides flexibility for both short‑term initiation and long‑term maintenance therapy.

How It Works

Teneligliptin functions by inhibiting the enzyme dipeptidyl peptidase‑4, which rapidly degrades incretin hormones such as glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). These hormones are released from the intestinal mucosa in response to nutrient intake and act on the pancreas to stimulate insulin secretion in a glucose‑dependent manner while also suppressing glucagon release from the liver. By blocking DPP‑4, Teneligliptin prolongs the activity of GLP‑1 and GIP, leading to increased insulin release when blood glucose is elevated and decreased hepatic glucose production when glucose levels are high.

Because this mechanism is glucose‑dependent, the drug has minimal impact on insulin secretion when glucose levels are low, contributing to its favorable safety profile regarding hypoglycemia. In addition, inhibition of DPP‑4 may exert secondary anti‑inflammatory effects, although the clinical relevance of this observation is still under investigation.

Dosage Guidelines

The recommended dosage for adults is one 20 mg tablet taken orally once daily, with or without food. If a dose is missed, the patient should take it as soon as remembered unless it is close to the time of the next scheduled dose; in that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose to compensate for a missed dose is not recommended.

For patients with mild to moderate hepatic impairment, no dose adjustment is necessary. However, in patients with severe hepatic disease, caution is advised, and the prescribing clinician may consider a reduced dose. Renal impairment requires more careful dosing: patients with a creatinine clearance between 30–50 mL/min may retain the standard dose, while those with a clearance below 30 mL/min should receive a reduced dose of 10 mg once daily, if a lower strength is available, or under close medical supervision. The dosing recommendations are consistent with the product labeling provided by Glenmark and are aligned with guidance from the FDA.

Special populations, such as the elderly, do not require dose modification solely based on age, but clinicians should assess renal function and overall health status before initiating therapy. Patients should be instructed to swallow the tablet whole with water and not to crush or chew it. If an overdose is suspected, medical attention should be sought immediately, although overdose symptoms are not well defined in the literature.

Side Effects

Like all medications, Teneligliptin 20 mg can cause adverse effects. The most frequently reported side effects include nasopharyngitis (inflammation of the nasal passages), urinary tract infections, and headache. These events are usually mild and resolve without intervention. Less common but clinically important side effects comprise pancreatitis, severe joint pain, and hypersensitivity reactions such as rash or angioedema. If any signs of pancreatitis—such as persistent abdominal pain, nausea, or vomiting—occur, the medication should be discontinued and medical attention sought immediately. Patients should be instructed to report any new or worsening symptoms to their healthcare provider, especially if they experience severe skin reactions, difficulty breathing, or swelling of the face, lips, or throat.

The frequency of side effects is generally comparable to that reported with other DPP‑4 inhibitors, and serious adverse events are rare. Nevertheless, vigilance is essential, and patients should be counseled to seek immediate medical care if they develop unexplained severe abdominal pain, persistent vomiting, or signs of an allergic reaction.

Warnings and Precautions

Before initiating therapy, a thorough medical history should be obtained. Patients with a prior diagnosis of pancreatitis, severe renal insufficiency, or known hypersensitivity to Teneligliptin should discuss these conditions with their physician. Concomitant use of other antidiabetic agents is permissible, but dose adjustments may be necessary to prevent hypoglycemia, particularly when combined with insulin or sulfonylureas. Alcohol consumption should be moderated, as excessive intake can increase the risk of hypoglycemia and may exacerbate pancreatic stress.

Pregnant or breastfeeding women should only use Teneligliptin if the potential benefit outweighs the possible risk, and they must consult their obstetrician or healthcare provider before starting treatment. The drug is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Drug interactions are generally limited due to the minimal metabolism via cytochrome enzymes; however, caution is advised when co‑administering medications that affect renal function or that have a narrow therapeutic index. Patients should always provide a complete list of current medications, including over‑the‑counter drugs and herbal supplements, to their prescribing clinician. Concomitant use with strong renal excreted drugs such as rifampin may alter Teneligliptin levels, and such combinations should be monitored closely.

Frequently Asked Questions

1. What is the typical onset of action for Teneligliptin? The drug begins to lower blood glucose within a few hours after ingestion, with peak effect observed after approximately 24 hours, supporting once‑daily dosing and convenient adherence.
2. Can Teneligliptin be combined with other antidiabetic medications? Yes, it may be used alongside metformin, sulfonylureas, or insulin, but clinicians should monitor for hypoglycemia and adjust doses as needed to maintain safe glucose targets.
3. Is Teneligliptin safe during pregnancy or lactation? Human data are limited; animal studies have not shown teratogenic effects, but the medication should only be used if clearly needed, under medical supervision, and breastfeeding is generally discouraged while taking the drug due to potential excretion in milk.
4. How should the medication be stored? Store the tablets in their original packaging at room temperature, away from moisture and heat. Do not refrigerate, and keep the strip tightly closed to protect from humidity. Keep out of reach of children and pets.
5. Where can I find detailed prescribing information? Full prescribing details are available on the FDA website, on the Drugs.com monograph, and in the NIH’s database of approved drugs. Additional scientific background can be found in the Wikipedia entry and the NIH overview of DPP‑4 inhibitors.

For patient support, Glenmark provides a toll‑free helpline and printable medication guides that can be accessed through the company’s official website. These resources offer detailed instructions on proper dosing, storage, and what to do in case of a missed dose or suspected overdose.